Etienne Macedo1, Ulla Hemmila2, Sanjib Kumar Sharma3, Rolando Claure-Del Granado4, Henry Mzinganjira2, Emmanuel A Burdmann5, Jorge Cerdá6, John Feehally7, Fredric Finkelstein8, Guillermo García-García9, Vivekanand Jha10,11,12, Norbert H Lameire13, Euyhyun Lee14, Nathan W Levin15, Andrew Lewington16,17, Raúl Lombardi18, Michael V Rocco19, Eliah Aronoff-Spencer1, Marcello Tonelli20, Karen Yeates21, Giuseppe Remuzzi22, Ravindra L Mehta1. 1. Division of Nephrology, Department of Medicine, University of California San Diego, San Diego, California, United States of America. 2. College of Medicine, University of Malawi, Blantyre, Malawi. 3. Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal. 4. Division of Nephrology, Hospital Obrero #2-Caja Nacional de Salud, School of Medicine, Universidad Mayor de San Simón, Cochabamba, Bolivia. 5. LIM 12, Division of Nephrology, University of São Paulo Medical School, São Paulo, Brazil. 6. Division of Nephrology, Department of Medicine, Albany Medical College, Albany, New York, United States of America. 7. University of Leicester, Leicester, United Kingdom. 8. Yale University, New Haven, Connecticut, United States of America. 9. Hospital Civil de Guadalajara, University of Guadalajara Health Science Center, Guadalajara, Jalisco, Mexico. 10. George Institute for Global Health, University of New South Wales, New Delhi, India. 11. School of Public Health, Imperial College London, London, United Kingdom. 12. Manipal Academy of Higher Education, Manipal, India. 13. Nephrology Section, Department of Internal Medicine, University Hospital, Ghent, Belgium. 14. Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, California, United States of America. 15. Mount Sinai School of Medicine, Renal Research Institute, New York, New York, United States of America. 16. Department of Nephrology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 17. NIHR Leeds In Vitro Diagnostics Co-operative, Leeds, United Kingdom. 18. Department of Critical Care Medicine, Servicio Médico Integral, Montevideo, Uruguay. 19. Section of Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America. 20. University of Calgary, Calgary, Alberta, Canada. 21. Division of Nephrology, Department of Medicine, Queen's University, Kingston, Ontario, Canada. 22. Istituto di Ricerche Farmacologiche Mario Negri, Istituto di Ricovero e Cura a Carattere Scientifico, Bergamo, Italy.
Abstract
BACKGROUND: Acute kidney injury (AKI) is increasingly encountered in community settings and contributes to morbidity, mortality, and increased resource utilization worldwide. In low-resource settings, lack of awareness of and limited access to diagnostic and therapeutic interventions likely influence patient management. We evaluated the feasibility of the use of point-of-care (POC) serum creatinine and urine dipstick testing with an education and training program to optimize the identification and management of AKI in the community in 3 low-resource countries. METHODS AND FINDINGS: Patients presenting to healthcare centers (HCCs) from 1 October 2016 to 29 September 2017 in the cities Cochabamba, Bolivia; Dharan, Nepal; and Blantyre, Malawi, were assessed utilizing a symptom-based risk score to identify patients at moderate to high AKI risk. POC testing for serum creatinine and urine dipstick at enrollment were utilized to classify these patients as having chronic kidney disease (CKD), acute kidney disease (AKD), or no kidney disease (NKD). Patients were followed for a maximum of 6 months with repeat POC testing. AKI development was assessed at 7 days, kidney recovery at 1 month, and progression to CKD and mortality at 3 and 6 months. Following an observation phase to establish baseline data, care providers and physicians in the HCCs were trained with a standardized protocol utilizing POC tests to evaluate and manage patients, guided by physicians in referral hospitals connected via mobile digital technology. We evaluated 3,577 patients, and 2,101 were enrolled: 978 in the observation phase and 1,123 in the intervention phase. Due to the high number of patients attending the centers daily, it was not feasible to screen all patients to assess the actual incidence of AKI. Of enrolled patients, 1,825/2,101 (87%) were adults, 1,117/2,101 (53%) were females, 399/2,101 (19%) were from Bolivia, 813/2,101 (39%) were from Malawi, and 889/2,101 (42%) were from Nepal. The age of enrolled patients ranged from 1 month to 96 years, with a mean of 43 years (SD 21) and a median of 43 years (IQR 27-62). Hypertension was the most common comorbidity (418/2,101; 20%). At enrollment, 197/2,101 (9.4%) had CKD, and 1,199/2,101 (57%) had AKD. AKI developed in 30% within 7 days. By 1 month, 268/978 (27%) patients in the observation phase and 203/1,123 (18%) in the intervention phase were lost to follow-up. In the intervention phase, more patients received fluids (observation 714/978 [73%] versus intervention 874/1,123 [78%]; 95% CI 0.63, 0.94; p = 0.012), hospitalization was reduced (observation 578/978 [59%] versus intervention 548/1,123 [49%]; 95% CI 0.55, 0.79; p < 0.001), and admitted patients with severe AKI did not show a significantly lower mortality during follow-up (observation 27/135 [20%] versus intervention 21/178 [11.8%]; 95% CI 0.98, 3.52; p = 0.057). Of 504 patients with kidney function assessed during the 6-month follow-up, de novo CKD arose in 79/484 (16.3%), with no difference between the observation and intervention phase (95% CI 0.91, 2.47; p = 0.101). Overall mortality was 273/2,101 (13%) and was highest in those who had CKD (24/106; 23%), followed by those with AKD (128/760; 17%), AKI (85/628; 14%), and NKD (36/607; 6%). The main limitation of our study was the inability to determine the actual incidence of kidney dysfunction in the health centers as it was not feasible to screen all the patients due to the high numbers seen daily. CONCLUSIONS: This multicenter, non-randomized feasibility study in low-resource settings demonstrates that it is feasible to implement a comprehensive program utilizing POC testing and protocol-based management to improve the recognition and management of AKI and AKD in high-risk patients in primary care.
BACKGROUND:Acute kidney injury (AKI) is increasingly encountered in community settings and contributes to morbidity, mortality, and increased resource utilization worldwide. In low-resource settings, lack of awareness of and limited access to diagnostic and therapeutic interventions likely influence patient management. We evaluated the feasibility of the use of point-of-care (POC) serum creatinine and urine dipstick testing with an education and training program to optimize the identification and management of AKI in the community in 3 low-resource countries. METHODS AND FINDINGS:Patients presenting to healthcare centers (HCCs) from 1 October 2016 to 29 September 2017 in the cities Cochabamba, Bolivia; Dharan, Nepal; and Blantyre, Malawi, were assessed utilizing a symptom-based risk score to identify patients at moderate to high AKI risk. POC testing for serum creatinine and urine dipstick at enrollment were utilized to classify these patients as having chronic kidney disease (CKD), acute kidney disease (AKD), or no kidney disease (NKD). Patients were followed for a maximum of 6 months with repeat POC testing. AKI development was assessed at 7 days, kidney recovery at 1 month, and progression to CKD and mortality at 3 and 6 months. Following an observation phase to establish baseline data, care providers and physicians in the HCCs were trained with a standardized protocol utilizing POC tests to evaluate and manage patients, guided by physicians in referral hospitals connected via mobile digital technology. We evaluated 3,577 patients, and 2,101 were enrolled: 978 in the observation phase and 1,123 in the intervention phase. Due to the high number of patients attending the centers daily, it was not feasible to screen all patients to assess the actual incidence of AKI. Of enrolled patients, 1,825/2,101 (87%) were adults, 1,117/2,101 (53%) were females, 399/2,101 (19%) were from Bolivia, 813/2,101 (39%) were from Malawi, and 889/2,101 (42%) were from Nepal. The age of enrolled patients ranged from 1 month to 96 years, with a mean of 43 years (SD 21) and a median of 43 years (IQR 27-62). Hypertension was the most common comorbidity (418/2,101; 20%). At enrollment, 197/2,101 (9.4%) had CKD, and 1,199/2,101 (57%) had AKD. AKI developed in 30% within 7 days. By 1 month, 268/978 (27%) patients in the observation phase and 203/1,123 (18%) in the intervention phase were lost to follow-up. In the intervention phase, more patients received fluids (observation 714/978 [73%] versus intervention 874/1,123 [78%]; 95% CI 0.63, 0.94; p = 0.012), hospitalization was reduced (observation 578/978 [59%] versus intervention 548/1,123 [49%]; 95% CI 0.55, 0.79; p < 0.001), and admitted patients with severe AKI did not show a significantly lower mortality during follow-up (observation 27/135 [20%] versus intervention 21/178 [11.8%]; 95% CI 0.98, 3.52; p = 0.057). Of 504 patients with kidney function assessed during the 6-month follow-up, de novo CKD arose in 79/484 (16.3%), with no difference between the observation and intervention phase (95% CI 0.91, 2.47; p = 0.101). Overall mortality was 273/2,101 (13%) and was highest in those who had CKD (24/106; 23%), followed by those with AKD (128/760; 17%), AKI (85/628; 14%), and NKD (36/607; 6%). The main limitation of our study was the inability to determine the actual incidence of kidney dysfunction in the health centers as it was not feasible to screen all the patients due to the high numbers seen daily. CONCLUSIONS: This multicenter, non-randomized feasibility study in low-resource settings demonstrates that it is feasible to implement a comprehensive program utilizing POC testing and protocol-based management to improve the recognition and management of AKI and AKD in high-risk patients in primary care.
Authors: Gregorio T Obrador; Ulla T Schultheiss; Matthias Kretzler; Robyn G Langham; Masaomi Nangaku; Roberto Pecoits-Filho; Carol Pollock; Jerome Rossert; Ricardo Correa-Rotter; Peter Stenvinkel; Robert Walker; Chih-Wei Yang; Caroline S Fox; Anna Köttgen Journal: Kidney Int Suppl (2011) Date: 2017-09-20
Authors: Lowell J Lo; Alan S Go; Glenn M Chertow; Charles E McCulloch; Dongjie Fan; Juan D Ordoñez; Chi-yuan Hsu Journal: Kidney Int Date: 2009-07-29 Impact factor: 10.612
Authors: S Finlay; B Bray; A J Lewington; C T Hunter-Rowe; A Banerjee; J M Atkinson; M C Jones Journal: Clin Med (Lond) Date: 2013-06 Impact factor: 2.659
Authors: Areef Ishani; Jay L Xue; Jonathan Himmelfarb; Paul W Eggers; Paul L Kimmel; Bruce A Molitoris; Allan J Collins Journal: J Am Soc Nephrol Date: 2008-11-19 Impact factor: 14.978
Authors: Anthony Batte; Sahit Menon; John M Ssenkusu; Sarah Kiguli; Robert Kalyesubula; Joseph Lubega; Zachary Berrens; Edrisa Ibrahim Mutebi; Rodney Ogwang; Robert O Opoka; Chandy C John; Andrea L Conroy Journal: Kidney Int Date: 2022-06-17 Impact factor: 18.998
Authors: Ana Cristina Dos Santos; Simone Luzia Fidelis de Oliveira; Virgílio Luiz Marques de Macedo; Paula Lauane Araujo; Francine Salapata Fraiberg; Nélliton Fernandes Bastos; Richard Lucas Alves; Carlos Darwin Gomes da Silveira; Sérgio Eduardo Soares Fernandes; Francisco de Assis Rocha Neves; Fábio Ferreira Amorim Journal: Sci Rep Date: 2022-03-03 Impact factor: 4.996
Authors: O C Pantoja-Gómez; S Realpe; Ginna Cabra-Bautista; J M Restrepo; O L Prado; A M Velasco; G E Martínez; S Leal; A Vallejo; Jose Andrés Calvache Journal: BMC Pediatr Date: 2022-03-15 Impact factor: 2.125